This chapter describes urogenital system drugs, which include spironolactone, frusemide, hydrochlorothiazide, torasemide, acetazolamide, finasteride, tamsulosin, oxybutynin, tolterodine, triamterene, dutasteride, ammonium chloride, bethanechol, flavoxate, and citric acid. Edema, hepatic cirrhosis with ascites and edema, diagnosis of primary hyperaldosteronism, preoperative management of hyperaldosteronism, hypertension, severe congestive heart failure (CHF), and diuretic-induced hypokalemia are the indications of spironolactone. Anuria, hyperkalemia, acute or progressive renal insufficiency, and Addison’s disease are the contraindications of spironolactone. Hypertension, edema associated with heart failure, pulmonary edema, and oliguria in acute or chronic renal failure are the indications of frusemide. Benign prostatic hyperplasia is the indication of finasteride.